VolitionRx (VNRX) Competitors $0.65 +0.06 (+10.53%) (As of 03:39 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends VNRX vs. FULC, ACB, FATE, LXEO, DMAC, ZNTL, ATAI, TNYA, ACRS, and ACRVShould you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Atai Life Sciences (ATAI), Tenaya Therapeutics (TNYA), Aclaris Therapeutics (ACRS), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. VolitionRx vs. Fulcrum Therapeutics Aurora Cannabis Fate Therapeutics Lexeo Therapeutics DiaMedica Therapeutics Zentalis Pharmaceuticals Atai Life Sciences Tenaya Therapeutics Aclaris Therapeutics Acrivon Therapeutics VolitionRx (NYSE:VNRX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Does the MarketBeat Community prefer VNRX or FULC? Fulcrum Therapeutics received 93 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 61.25% of users gave Fulcrum Therapeutics an outperform vote while only 11.63% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVolitionRxOutperform Votes511.63%Underperform Votes3888.37% Fulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Is VNRX or FULC more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Fulcrum Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% Fulcrum Therapeutics N/A -7.31%-6.74% Which has higher valuation & earnings, VNRX or FULC? VolitionRx has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$1.29M45.71-$35.32M-$0.36-1.76Fulcrum Therapeutics$80.87M2.89-$97.33M-$0.31-14.00 Which has more risk and volatility, VNRX or FULC? VolitionRx has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Do analysts prefer VNRX or FULC? VolitionRx presently has a consensus target price of $3.75, indicating a potential upside of 491.20%. Fulcrum Therapeutics has a consensus target price of $9.33, indicating a potential upside of 115.05%. Given VolitionRx's stronger consensus rating and higher probable upside, equities analysts plainly believe VolitionRx is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media refer more to VNRX or FULC? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than VolitionRx. MarketBeat recorded 5 mentions for Fulcrum Therapeutics and 3 mentions for VolitionRx. Fulcrum Therapeutics' average media sentiment score of 0.80 beat VolitionRx's score of 0.67 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VolitionRx 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of VNRX or FULC? 8.1% of VolitionRx shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 12.8% of VolitionRx shares are owned by insiders. Comparatively, 4.1% of Fulcrum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryFulcrum Therapeutics beats VolitionRx on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get VolitionRx News Delivered to You Automatically Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNRX vs. The Competition Export to ExcelMetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$58.78M$2.61B$5.15B$19.68BDividend YieldN/A0.74%4.81%3.51%P/E Ratio-1.766.29135.4243.79Price / Sales45.7168.501,184.6217.84Price / CashN/A15.1640.4221.73Price / Book-5.773.374.895.48Net Income-$35.32M$29.98M$118.71M$987.88M7 Day Performance-4.76%-2.68%15.74%-2.00%1 Month Performance-6.72%13.78%15.70%1.00%1 Year Performance-16.54%-19.21%34.85%16.82% VolitionRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNRXVolitionRx2.0902 of 5 stars$0.65+10.5%$3.75+476.0%-22.6%$60.33M$1.29M-1.8180High Trading VolumeFULCFulcrum Therapeutics1.8866 of 5 stars$4.42+11.6%$9.33+111.2%-15.8%$238.41M$80.87M-13.68100ACBAurora Cannabis0.2987 of 5 stars$4.29-0.5%N/A-6.9%$235.26M$200.35M-5.671,073FATEFate Therapeutics3.7125 of 5 stars$2.05+12.0%$6.75+229.3%-37.7%$233.48M$13.45M-1.22550Short Interest ↑LXEOLexeo Therapeutics3.0562 of 5 stars$6.99+1.6%$23.80+240.5%-44.4%$231.13M$650,000.00-2.1858Positive NewsDMACDiaMedica Therapeutics3.0067 of 5 stars$5.37-0.2%$7.00+30.4%+89.1%$229.62MN/A-9.6120Short Interest ↓News CoveragePositive NewsZNTLZentalis Pharmaceuticals2.5782 of 5 stars$3.22+4.2%$10.00+210.6%-78.7%$229.46MN/A-1.24160ATAIAtai Life Sciences3.0279 of 5 stars$1.34-1.5%$9.00+571.6%+4.8%$224.86M$331,000.00-1.6883Positive NewsTNYATenaya Therapeutics3.9767 of 5 stars$2.82+2.5%$17.33+514.7%-32.2%$223.40MN/A-1.91110Analyst ForecastNews CoverageACRSAclaris Therapeutics3.7688 of 5 stars$3.06-5.0%$8.80+187.6%+222.8%$218.58M$31.25M-6.1986Positive NewsACRVAcrivon Therapeutics1.4082 of 5 stars$7.02-0.6%$23.67+237.1%+57.1%$218.58MN/A-2.6158 Related Companies and Tools Related Companies FULC Alternatives ACB Alternatives FATE Alternatives LXEO Alternatives DMAC Alternatives ZNTL Alternatives ATAI Alternatives TNYA Alternatives ACRS Alternatives ACRV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:VNRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
